ADCT vs. GERN

Last updated Apr 1, 2026

Compare and contrast key facts about ADC Therapeutics SA (ADCT) and Geron Corporation (GERN).

Performance

ADCT vs. GERN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ADC Therapeutics SA (ADCT) and Geron Corporation (GERN). The values are adjusted to include any dividend payments, if applicable.

ADCT vs. GERN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ADCT ADC Therapeutics SA	6.23%	77.39%	19.88%	-56.77%	-80.99%	-36.89%	7.96%
GERN Geron Corporation	12.88%	-62.71%	67.77%	-12.81%	98.36%	-23.27%	-9.14%

Fundamentals

Market Cap ADCT : $563.63M GERN : $994.08M
EPS ADCT : -$1.07 GERN : -$0.13
PS Ratio ADCT : 6.81 GERN : 5.40
Total Revenue (TTM) ADCT : $73.55M GERN : $183.88M
Gross Profit (TTM) ADCT : $67.75M GERN : $158.07M
EBITDA (TTM) ADCT : -$112.61M GERN : -$39.32M

Returns By Period

In the year-to-date period, ADCT achieves a 6.23% return, which is significantly lower than GERN's 12.88% return.

ADCT

• 1D: 3.02%
• 1M: -8.54%
• YTD: 6.23%
• 6M: -6.25%
• 1Y: 165.96%
• 3Y*: 24.36%
• 5Y*: -31.86%
• 10Y*: —

GERN

• 1D: 5.67%
• 1M: -11.31%
• YTD: 12.88%
• 6M: 8.76%
• 1Y: -6.29%
• 3Y*: -11.78%
• 5Y*: -1.66%
• 10Y*: -6.76%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ADCT vs. GERN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ADCT

ADCT Risk / Return Rank: 89
ADCT Sharpe Ratio Rank: 90
ADCT Sortino Ratio Rank: 89
ADCT Omega Ratio Rank: 83
ADCT Calmar Ratio Rank: 93
ADCT Martin Ratio Rank: 89

GERN

GERN Risk / Return Rank: 36
GERN Sharpe Ratio Rank: 37
GERN Sortino Ratio Rank: 39
GERN Omega Ratio Rank: 37
GERN Calmar Ratio Rank: 33
GERN Martin Ratio Rank: 33

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ADCT vs. GERN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ADC Therapeutics SA (ADCT) and Geron Corporation (GERN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ADCT	GERN	Difference
Sharpe ratio Return per unit of total volatility	1.93	-0.09	+2.02
Sortino ratio Return per unit of downside risk	2.79	0.36	+2.43
Omega ratio Gain probability vs. loss probability	1.32	1.04	+0.28
Calmar ratio Return relative to maximum drawdown	4.98	-0.29	+5.27
Martin ratio Return relative to average drawdown	10.11	-0.53	+10.64
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ADCT vs. GERN - Sharpe Ratio Comparison

The current ADCT Sharpe Ratio is 1.93, which is higher than the GERN Sharpe Ratio of -0.09. The chart below compares the historical Sharpe Ratios of ADCT and GERN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ADCT	GERN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.93	-0.09	+2.02
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.33	-0.02	-0.31
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.09	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.32	-0.06	-0.26

Correlation

The correlation between ADCT and GERN is 0.33, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ADCT vs. GERN - Dividend Comparison

Neither ADCT nor GERN has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ADCT vs. GERN - Drawdown Comparison

The maximum ADCT drawdown since its inception was -99.08%, roughly equal to the maximum GERN drawdown of -98.73%. Use the drawdown chart below to compare losses from any high point for ADCT and GERN.

Drawdown Indicators

	ADCT	GERN	Difference
Max Drawdown Largest peak-to-trough decline	-99.08%	-98.73%	-0.35%
Max Drawdown (1Y) Largest decline over 1 year	-30.45%	-33.95%	+3.50%
Max Drawdown (5Y) Largest decline over 5 years	-98.51%	-78.98%	-19.53%
Max Drawdown (10Y) Largest decline over 10 years	—	-86.09%	—
Current Drawdown Current decline from peak	-92.65%	-97.87%	+5.22%
Average Drawdown Average peak-to-trough decline	-76.88%	-86.08%	+9.20%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.01%	18.29%	-3.28%

Volatility

ADCT vs. GERN - Volatility Comparison

ADC Therapeutics SA (ADCT) has a higher volatility of 22.65% compared to Geron Corporation (GERN) at 21.18%. This indicates that ADCT's price experiences larger fluctuations and is considered to be riskier than GERN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ADCT	GERN	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.65%	21.18%	+1.47%
Volatility (6M) Calculated over the trailing 6-month period	50.01%	46.58%	+3.43%
Volatility (1Y) Calculated over the trailing 1-year period	86.91%	67.84%	+19.07%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	96.69%	82.34%	+14.35%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	92.81%	77.96%	+14.85%

Financials